Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
News|Articles|May 3, 2026
April’s GI Monthly Rewind: Key Regulatory Updates You May Have Missed
Author(s)Courtney Flaherty
Fact checked by: Kyle Doherty
A one-stop-shop for regulatory updates across GI malignancies from the past month.
Advertisement
Advertisement
April’s gastrointestinal (GI) regulatory landscape was characterized by a surge in specialized FDA designations aimed at accelerating the development of precision tools for difficult-to-treat malignancies. Of note, the FDA granted priority review to zanidatamab-hrii (Ziihera)–based regimens for HER2-positive gastroesophageal adenocarcinoma (GEA) and accepted a supplemental biologics license application (sBLA) for zenocutuzumab-zbco (Bizengri) in NRG1 fusion–positive cholangiocarcinoma.1,3
Related to this article
Results from an early-stage clinical trial found encouraging outcomes in newly diagnosed pancreatic cancer that had spread to distant organs.
Read a refresh of GI cancer FDA news from August 2026, including the approval of a RAS(ON) inhibitor in metastatic pancreatic cancer.
The FDA has approved lirafugratinib (Lyrfigtu) for the treatment of adult patients with previously treated unresectable, locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 gene fusion or other rearrangement.
Lanreotide injection, a generic formulation referencing lanreotide, was approved by the FDA for GEP-NETs management.
The FDA granted final approval to Lutetium Lu 177 dotatate biosimilar for patients with SSTR-positive GEP-NETs.
The FDA approved imlunestrant plus abemaciclib in breast cancer and photodynamic therapy in skin cancer, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
Advertisement